Trading · Founded 1992 · www.integratedproteins.com · BSE 519606 · · ISIN INE177M01021
No Notes Added Yet
Business
Integrated Proteins Ltd. operates in the trading sector within India. The company's core business model involves acting as an intermediary for the sourcing, distribution, and sale of protein-related commodities. Given its name, it likely specializes in various forms of proteins, potentially including animal feed proteins (e.g., soybean meal, fish meal), food-grade proteins (e.g., soy protein isolates, wheat gluten), or other related agri-commodities. The company makes money through trading margins, which is the difference between its buying and selling prices, by leveraging its network of suppliers and buyers, market intelligence, and logistical capabilities.
Revenue Mix
While specific segment data is not available, based on the company name and industry, potential segments for Integrated Proteins Ltd. could include:
Animal Feed Proteins: Trading of protein ingredients used in animal nutrition.
Food & Industrial Proteins: Trading of proteins for human consumption or industrial applications.
Other Agri-Commodities: Potentially diversifying into trading other agricultural products related to its protein focus.
Revenue generation is primarily from the sale of these traded commodities.
Industry
The trading industry in India is characterized by its competitive and often fragmented nature, especially in agricultural commodities. Success relies heavily on efficient sourcing, strong logistical networks, deep market intelligence, and robust client relationships. Key players range from large global commodity houses to regional specialists and local brokers. Without specific market share data, Integrated Proteins Ltd. likely positions itself as a specialized player within the protein commodities segment, aiming to differentiate through reliable supply, competitive pricing, and efficient service within the Indian market.
MOAT
Trading companies generally possess limited sustainable competitive advantages. For Integrated Proteins Ltd., potential advantages could stem from:
Established Relationships: Long-standing and trusted relationships with a diverse base of suppliers and buyers, ensuring consistent deal flow.
Logistical Efficiency: An optimized supply chain, including warehousing and transportation, that minimizes costs and delivery times.
Market Intelligence: Superior real-time insights into supply-demand dynamics, pricing trends, and regulatory changes, enabling informed trading decisions.
Financial Strength: The ability to manage working capital effectively and offer favorable credit terms can be crucial in a high-volume, low-margin business.
Growth Drivers
Rising Protein Demand: Global and domestic population growth, increasing disposable incomes, and evolving dietary preferences are driving higher demand for protein.
Geographic Expansion: Entering new domestic regions or international markets for sourcing or distribution.
Product Diversification: Expanding the range of protein types or related agri-commodities traded.
Value-Added Services: Potentially offering basic processing, blending, or specific formulation services to customers.
Supply Chain Optimization: Continuous improvement in logistics and sourcing efficiency to enhance margins and competitiveness.
Risks
Commodity Price Volatility: Significant fluctuations in global and domestic protein commodity prices can severely impact trading margins and profitability.
Supply Chain Disruptions: Events such as adverse weather, geopolitical tensions, trade restrictions, or logistical bottlenecks can disrupt supply and raise costs.
Regulatory & Policy Changes: Changes in government policies regarding agriculture, trade, import/export duties, or food safety standards in India or target markets can affect operations.
Intense Competition: The fragmented nature of the trading industry leads to aggressive competition, potentially compressing margins.
Currency Fluctuations: For international trade, adverse movements in foreign exchange rates can erode profitability.
Working Capital Management: Trading businesses are capital intensive; inefficient management of working capital can strain liquidity.
Counterparty Risk: Risk of default by buyers or suppliers.
Management & Ownership
Specific details regarding Integrated Proteins Ltd.'s promoters, management quality, and ownership structure are not provided. Typically, Indian trading companies are often promoter-driven, with significant ownership held by the founding family or core group. The quality of management would depend on their experience in commodity markets, risk management capabilities, and ability to foster strong relationships.
Outlook
Integrated Proteins Ltd. operates in a fundamental yet challenging sector. The ongoing global demand for protein, driven by population growth and changing diets, provides a long-term tailwind. Success will hinge on the company's ability to navigate the inherent volatility of commodity markets, maintain efficient operations, and leverage strong supplier and customer relationships. A disciplined approach to risk management, particularly regarding price fluctuations and currency exposure, will be crucial. Expansion into new products or geographies, coupled with continuous optimization of its supply chain, could fuel growth. Conversely, intense competition, unforeseen supply chain disruptions, and adverse regulatory shifts pose significant challenges that could impact profitability and market position.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 0 | 0 | 0 | 0 | 21 | 0 | 4 | 0 | 6 | 11 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 0 | 0 | 0 | 0 | 22 | 0 | 4 | 0 | 6 | 11 |
| Total Expenditure | 0 | 0 | 0 | 0 | 21 | 0 | 4 | 0 | 5 | 10 |
| Operating Profit | 0 | 0 | -0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | -0 | -0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 |
| Provision for Tax | 0 | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 0 | -0 | -0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 |
| Adjustments | 0 | 0 | 0 | -0 | -0 | 0 | 0 | 0 | -0 | 0 |
| Profit After Adjustments | 0 | -0 | -0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 |
| Adjusted Earnings Per Share | 0 | -0 | -0 | 0 | 0.1 | 0 | 0 | -0 | 0 | 0 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 21 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 22 | 21 |
| Total Expenditure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 19 |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Provision for Tax | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adjusted Earnings Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | 0 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 0% | 0% | 0% | 0% |
| Operating Profit CAGR | 0% | 0% | 0% | 0% |
| PAT CAGR | 0% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 337% | 122% | 103% | 19% |
| ROE Average | 10% | 5% | 4% | 3% |
| ROCE Average | 2% | 3% | 2% | 2% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 2 | 2 | 3 | 3 | 2 | 2 | 2 | 2 | 3 | 3 | 20 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 |
| Total Liabilities | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 32 |
| Fixed Assets | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 |
| Total Current Assets | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 32 |
| Total Assets | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 32 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow from Operating Activities | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -24 |
| Cash Flow from Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 2 |
| Cash Flow from Financing Activities | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | -0 | 21 |
| Net Cash Inflow / Outflow | 0 | 0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.03 | 0.02 | 0.01 | 0 | 0.01 | 0 | 0.01 | 0.01 | 0.01 | 0.03 | 0.08 |
| CEPS(Rs) | 0.03 | 0.03 | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 | 0.04 | 0.08 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 0.68 | 0.71 | 0.72 | 0.69 | 0.66 | 0.66 | 0.67 | 0.68 | 0.69 | 0.72 | 0.79 |
| Core EBITDA Margin(%) | -58.14 | -77.64 | 0 | 0 | 0 | 0 | 0 | 0 | -51.14 | -49.87 | 0.43 |
| EBIT Margin(%) | 105.32 | 103.54 | 0 | 0 | 0 | 0 | 0 | 0 | 25.09 | 43.85 | 1.49 |
| Pre Tax Margin(%) | 101.4 | 102.4 | 0 | 0 | 0 | 0 | 0 | 0 | 25.03 | 43.81 | 1.49 |
| PAT Margin (%) | 101.4 | 102.4 | 0 | 0 | 0 | 0 | 0 | 0 | 18.5 | 37.62 | 1.16 |
| Cash Profit Margin (%) | 136.03 | 139.42 | 0 | 0 | 0 | 0 | 0 | 0 | 35.75 | 48.74 | 1.21 |
| ROA(%) | 3.48 | 3.17 | 1.76 | 0.45 | 0.95 | 0.22 | 0.82 | 1.38 | 1.12 | 3.22 | 1.42 |
| ROE(%) | 3.72 | 3.39 | 1.91 | 0.51 | 1.14 | 0.26 | 1 | 1.69 | 1.41 | 3.97 | 10.34 |
| ROCE(%) | 3.87 | 3.43 | 3.34 | 2.54 | 0.15 | 0.76 | 1.17 | 1.95 | 1.59 | 3.89 | 2.4 |
| Receivable days | 31.35 | 86.82 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Payable days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 135.07 | 57.06 | 69.58 |
| PER(x) | 0 | 9.08 | 16.47 | 0 | 31.69 | 0 | 0 | 131.65 | 124.04 | 58.16 | 50.87 |
| Price/Book(x) | 0 | 0.3 | 0.31 | 0 | 0.37 | 0 | 0 | 2.21 | 1.74 | 2.27 | 5.01 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 36 | 3.13 | 0 | 0 | 0 | 0 | 0 | 0 | 23.95 | 21.76 | 0.77 |
| EV/Core EBITDA(x) | 25.72 | 2.23 | 2.77 | 30 | 13.79 | 63.29 | 55.09 | 62.02 | 56.56 | 39.59 | 50.22 |
| Net Sales Growth(%) | 22.73 | -6.48 | -100 | 0 | 0 | 0 | 0 | 0 | 0 | 42.16 | 8954.89 |
| EBIT Growth(%) | -17.38 | -8.06 | 0.05 | -23.18 | -94.09 | 386.54 | 55.12 | 72.13 | -15.18 | 148.45 | 206.92 |
| PAT Growth(%) | -20.33 | -5.56 | -42.3 | -74.44 | 102.59 | -77.53 | 281.19 | 72.17 | -15.34 | 189 | 179.96 |
| EPS Growth(%) | -20.32 | -5.57 | -42.3 | -71.99 | 102.89 | -77.49 | 280.32 | 72.17 | -15.3 | 188.81 | 180.01 |
| Debt/Equity(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.03 | 0.08 | 0.01 | 1.36 |
| Current Ratio(x) | 2.54 | 2.75 | 2.29 | 12.33 | 3.72 | 3.05 | 1.14 | 0.72 | 0.84 | 1.2 | 2.64 |
| Quick Ratio(x) | 2.54 | 2.75 | 2.29 | 12.33 | 3.72 | 3.05 | 1.14 | 0.72 | 0.84 | 1.2 | 2.64 |
| Interest Cover(x) | 26.85 | 90.28 | 501.68 | 294.88 | 5.79 | 371.96 | 0 | 494 | 419 | 1041 | 3195 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 | 0.05 | 0.01 | 0.31 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 46.29 | 46.29 | 46.29 | 22.4 | 13.04 | 13.04 | 13.04 | 2.23 | 2.23 | 2.24 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 53.71 | 53.71 | 53.71 | 77.6 | 86.96 | 86.96 | 86.96 | 97.77 | 97.77 | 97.76 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.15 | 0.15 | 0.15 | 0.07 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.17 | 0.17 | 0.17 | 0.25 | 0.28 | 0.28 | 0.28 | 1.83 | 1.83 | 1.83 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 1.87 | 1.87 | 1.87 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | — | — | — | — |
| Operating Profit CAGR | — | — | — | — |
| PAT CAGR | — | — | — | — |
| Share Price CAGR | +337% | +122% | +103% | +19% |
| ROE Average | +10% | +5% | +4% | +3% |
| ROCE Average | +2% | +3% | +2% | +2% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 46.29 | 46.29 | 46.29 | 22.4 | 13.04 | 13.04 | 13.04 | 2.23 | 2.23 | 2.24 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 53.71 | 53.71 | 53.71 | 77.6 | 86.96 | 86.96 | 86.96 | 97.77 | 97.77 | 97.76 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.15 | 0.15 | 0.15 | 0.07 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.17 | 0.17 | 0.17 | 0.25 | 0.28 | 0.28 | 0.28 | 1.83 | 1.83 | 1.83 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 1.87 | 1.87 | 1.87 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.